Skip to main content
OpenTrials
Completed

NCT Number: NCT05153915

A Study to Evaluate the Safety and Efficacy of a Modigraf® Based Immunosuppression Regimen in De Novo Pediatric Allograft Liver and Kidney Transplantation Recipients

The purpose of this study is to observe the safety and efficacy of Modigraf in de novo pediatric allograft liver and kidney transplantation recipients. This study will also monitor dose changes and tacrolimus whole blood trough levels of Modigraf based immunosuppression regimen.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Liver Transplantation Kidney Transplantation

Age range

Up to 17 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Site CN86003, Beijing, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participant's parent(s) or their legal representative(s), and participant where applicable agrees not to participate in another interventional study while participating in the present study from 1 month before screening to the end of the study.

Exclusion criteria

  • Participant has previously received another organ transplant.
  • Participant has a high immunological risk, defined as a panel reactive antibody (PRA) score > 50% in the previous 6 months (only applicable for kidney transplantation recipients).
  • Cold ischemia time of the donor kidney longer than 30 hours (only applicable for kidney transplantation recipients).
  • Bilateral kidney transplantation recipients (only applicable for kidney transplantation recipients).
  • Participant receives an ABO incompatible donor organ.
  • Participant has significant kidney impairment, defined as having serum creatinine ≥ 230 μmol/L (≥ 2.6 mg/dL) prior to transplantation (not applicable for kidney transplantation recipients).
  • Participant has significant liver disease, defined as having elevated alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) and/or total bilirubin (TBL) levels 3 times the upper value of the normal range prior to transplantation (not applicable for liver transplantation recipients).
  • Participants with malignancies or a history of malignancy within the last 5 years.
  • Participant has a significant, uncontrolled systemic infection and/or severe diarrhea, vomiting, active upper gastrointestinal disorder that may affect the absorption of tacrolimus or has an active peptic ulcer.
  • Recipient or donor known to be human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV) positive.
  • Participant requires systemic immunosuppressive medication for any indication other than transplantation.
  • Participants taking or requiring to be treated with medication or substances prohibited by this protocol.
  • Known allergy or intolerance to steroids, macrolide antibiotics, basiliximab, or tacrolimus.
  • Participants with severe primary disease/complications/poor general condition which may be unsuitable for participating in this study.
  • Participant is currently participating in another clinical trial and/or has been taking any other study drug within 1 month prior to screening.
  • Participant is unlikely to comply with the visits scheduled in the protocol.

Treatment and study plan

Tacrolimus granules

Drug

Oral

Other names: Modigraf

Primary outcomes

  1. Percentage of Participants With Acute Rejection (AR)

    Time frame: From first dose to month 12

    AR is an immune response against the donor graft that causes tissue impairment and potential failure. The criteria for rejection was performed by the local histopathologist following the "Histological Grading of Liver Biopsies for Rejection", the "Banff diagnostic categories for renal allograft biopsies".

  2. Percentage of Participants with Biopsy-Proven Acute Rejections (BPAR)

    Time frame: From first dose to month 12

    AR is an immune response against the donor graft that causes tissue impairment and potential failure. The criteria for rejection was performed by the local histopathologist following the "Histological Grading of Liver Biopsies for Rejection", the "Banff diagnostic categories for renal allograft biopsies". A BPAR episode was defined as any AR episode confirmed by biopsy.

  3. Percentage of Participants with clinically suspected Rejection

    Time frame: From first dose to month 12

    AR is an immune response against the donor graft that causes tissue impairment and potential failure. The criteria for rejection was performed by the local histopathologist following the "Histological Grading of Liver Biopsies for Rejection", the "Banff diagnostic categories for renal allograft biopsies". An AR was clinically suspected in participants who experienced an increase in serum creatinine, after the exclusion of other causes of graft dysfunction (generally with biopsy).

  4. Number of Participants who Died

    Time frame: From first dose to month 12

    Number of participants who died is recorded during 12 months' post-transplant; any cause of death was taken into account.

  5. Number of participants with graft failure

    Time frame: From first dose to month 12

    Graft failure is defined as graft dysfunction including re-transplantation, graft loss or death, during the study period. A graft dysfunction to permanent dialysis in kidney transplantation was also considered as graft failure.

  6. Number of dose adjustments throughout the study period

    Time frame: From first dose to month 12

    The number of dose changes will The dose adjustments required for the organ transplant were reported. The Safety Analysis Set (SAF) consisted of all participants who took at least one dose of study drug.

  7. Number of participants with Treatment Emergent adverse events (AEs)

    Time frame: From first dose to month 12

    An AE is defined as any untoward medical occurrence in a participant administered a study drug not necessarily linked to this treatment. An AE can be any unfavorable and unintended sign (e.g., abnormal laboratory finding; abnormal laboratory test result or other safety assessment, symptom, or disease temporally associated with the use of a study drug, whether or not considered related to the study drug. Treatment emergent adverse event (TEAE) is defined as AE observed after administering the study drug.

  8. Whole Blood Trough Levels of Tacrolimus

    Time frame: From month 1 through month 12 (predose)

    Tacrolimus whole blood trough levels are routinely monitored from whole blood samples, using a local assay method, for example EMITÒ or Liquid-Chromatography-Mass-Spectrometry-Mass-Spectrometry (LC-MS-MS) in the local laboratories.

Sponsors and collaborators

Lead sponsor

Astellas Pharma China, Inc.

Industry

Registry information

Official study title

A Long-term, Open-label, Non-comparative Study to Evaluate the Safety and Efficacy of a Modigraf® Based Immunosuppression Regimen in De Novo Pediatric Allograft Liver and Kidney Transplantation Recipients

Important dates

Study start
2021
Primary completion
2024
Study completion
2024
First posted
Dec 10, 2021
Registry last updated
Mar 17, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.